REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.9B+21.8% YoY

Gross Profit

$1.8B91.7% margin

Operating Income

$718M37.2% margin

Net Income

$820M42.6% margin

EPS (Diluted)

$7.15

QoQ Revenue Growth

+15.9%

Cash Flow

Operating Cash Flow

$729M

Free Cash Flow

$643M

Stock-Based Comp.

$127M

Balance Sheet

Total Assets

$11.7B

Total Liabilities

$3.0B

Stockholders' Equity

$8.8B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.9B	$1.6B	+21.8%
Gross Profit	$1.8B	$1.4B	+22.6%
Operating Income	$718M	$539M	+33.3%
Net Income	$820M	$174M	+372.8%

Revenue Segments

Product

$2.1B100%

REGN Q4 2018 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena